Population pharmacokinetics of peramivir in healthy volunteers and influenza patients

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6755-6762

  Matsuo, Yumiko ^a   Ishibashi, Toru ^a   Hollister, Alan S ^b,c   Wajima, Toshihiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

^c Clinical Pharmacology Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PERAMIVIR; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CENTRAL VOLUME OF DISTRIBUTION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; INFLUENZA; JAPAN; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; MONTE CARLO METHOD; PERIPHERAL VOLUME OF DISTRIBUTION; PRIORITY JOURNAL; RACE DIFFERENCE; SEVERE RENAL IMPAIRMENT; SEX DIFFERENCE; UNITED STATES; BLOOD; CLINICAL TRIAL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; THEORETICAL MODEL;

CYCLOPENTANES; GUANIDINES; HEALTHY VOLUNTEERS; HUMANS; INFLUENZA, HUMAN; JAPAN; MODELS, THEORETICAL; MONTE CARLO METHOD; UNITED STATES;

EID: 84946209254     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00799-15     Document Type: Article

References (20)

1. Bantia S, Parker CD, Ananth S.L., Horn LL, Andries K, Chand P, Kotian P.L., Dehghani A., El-Kattan Y, Lin T, Hutchison T.L., Montgomery JA, Kellog DL, Babu YS. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 45:1162-1167. http://dx.doi.org/10.1128/AAC.45.4.1162-1167.2001.
2. Bantia S, Arnold CS, Parker C.D., Upshaw R., Chand P. 2006. Antiinfluenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 69:39-45. http://dx.doi.org/10.1016/j.antiviral.2005.10.002.
3. Gubareva LV, Webster RG, Hayden FG 2001. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45:3403-3408. http://dx.doi.org/10.1128/AAC.45.12.3403-3408.2001.
4. Hayden F. 2009. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48:S3-S13. http://dx.doi.org/10.1086/591851.
5. Centers for Disease Control and Prevention. 2009. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 58:433-435.
6. Kohno S, Kida H, Mizuguchi M., Shimada J, for the S-021812 Clinical Study Group. 2010. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 54:4568-4574. http://dx.doi.org/10.1128/AAC.00474-10.
7. Kohno S, Yen MY, Cheong H.J., Hirotsu N., Ishida T, Kadota J, Mizuguchi M., Kida H, Shimada J, the S-021812 Clinical Study Group. 2011. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 55:5267-5276. http://dx.doi.org/10.1128/AAC.00360-11.
8. Kohno S, Kida H, Mizuguchi M., Hirotsu N, Ishida T, Kadota J., Shimada J, the S-021812 Clinical Study Group. 2011. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 55:2803-2812. http://dx.doi.org/10.1128/AAC.01718-10.
9. Shionogi & Co., Ltd. 2010. Rapiacta for intravenous drip infusion: package insert. Shionogi & Co., Ltd, Osaka, Japan. (In Japanese.)
10. BioCryst Pharmaceuticals, Inc. 2014. Rapivab (peramivir injection), for intravenous use: prescribing information. BioCryst Pharmaceuticals, Inc., Durham, NC.
11. Pharmaceuticals and Medical Devices Agency. 2011. Common technical documents for Japanese new drug application for rapiacta. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. http://database.japic.or.jp/pdf/newPINS/00060652.pdf
12. Beigel J, Harman LA, Collis P.J., Mccullough A., Kilpatrick JM, Ruff D, Mead E, Alexander WJ 2007. Pharmacokinetic and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteers, poster A-1408. Abstr 47th Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC
13. Collis PJ, Harman LA, Kilpatrick J.M., Denoia E., Mead E, Noonan P, Alexander WJ 2007. A placebo-controlled evaluation of the safety and pharmacokinetics of multiple-dose intravenous administration of peramivir to healthy elderly subjects, poster A-1409. Abstr 47th Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC.
14. Swan S, Marbury T, Smith W., Levasseur L, Elder J, Alexander W., Harman L, Collis P. 2009. Safety and pharmacokinetics of peramivir following intravenous administration in subjects with renal impairment, poster 623. Abstr 47th Annu Meet Infect Dis Soc Am, Philadelphia, PA
15. Beal SL, Sheiner LB (ed). 1992. NONMEM users' guides. NONMEM Project Group, University of California at San Francisco, San Francisco, CA.
16. Cockcroft DW, Gault MH 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
17. Ette EL, Williams PJ, Kim Y.H., Lane JR, Liu MJ, Cappareli EV. 2003. Model appropriateness and population pharmacokinetics modeling. J Clin Pharmacol 43:610-623. http://dx.doi.org/10.1177/0091270003253624.
18. Holford NG. 2005. PAGE 14, abstr 738. Population Approach Group in Europe, Pamplona, Spain. http://www.page-meeting.org/?abstr=738.
19. Karlsson MO, Holford H. 2008. PAGE 17, abstr 1434. Population Approach Group in Europe, Marseille, France. http://www.page-meeting.org/?abstr=1434.
20. Food and Drug Administration. 1998. Guidance for industry: pharmacokinetics in patients with impaired renal function. Food and Drug Administration, Rockville, MD.